Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

84.82 -0.25 (-0.29%)
Streaming Delayed Price Updated: 3:32 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
From Arcellx, Inc.
Via Business Wire
Decoding 8 Analyst Evaluations For Arcellx
 
Via Benzinga
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
The Latest Analyst Ratings For Arcellx
 
Via Benzinga
Expert Ratings For Arcellx
 
Via Benzinga
Analyst Expectations For Arcellx's Future
 
Via Benzinga
Peering Into Arcellx's Recent Short Interest
 
Via Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Arcellx, Inc.
Via Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Arcellx Analysts Boost Their Forecasts After Q4 Results
Arcellx, Inc. (NASDAQ: ACLX) posted financial results for its fourth quarter on Wednesday. 
Via Benzinga
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
 
Via Benzinga
Where Arcellx Stands With Analysts
 
Via Benzinga
Arcellx Provides First Quarter 2024 Financial Results
From Arcellx, Inc.
Via Business Wire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
Arcellx to Participate in Two Upcoming Investor Conferences
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Arcellx, Inc.
Via Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
A look at the bearish analog structure that the S&P 500 could be unfolding and the 3 warning signs you can't ignore. 
Via Talk Markets
Topics Stocks
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry. 
Via InvestorPlace
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction... 
Via Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or  
Via Benzinga
Chart Of The Day: Arcellx - Reimagining Cell Therapy
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.